INTRODUCTION: Bullous systemic lupus erythematosus (BSLE) is an autoantibody-mediated disease with subepidermal blisters. It is a rare form of presentation of SLE that occurs in less than 5% of cases ...

No adverse events occurred during treatment, and the patient's underlying comorbidities remained stable. Sequential therapy with spesolimab followed by dupilumab can be an effective and safe strategy ...

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP BP is a chronic, ...

Azacitidine is a hypomethylating agent recommended for the treatment of patients with high-risk myelodysplastic syndromes. Here, we report the case of a patient with myelodysplastic syndrome who was ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also significantly ...

Regeneron Pharmaceuticals and Sanofi have won Food and Drug Administration priority review of their application seeking expanded approval of their blockbuster anti-inflammatory drug Dupixent for ...

A Prescription Drug User Fee Act target date of June 20, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...

Linear IgA bullous dermatosis (LABD) is an autoimmune disease that causes blisters. People with LABD can develop blisters in the skin and the mucous membranes in their mouth, genitals, and eyelids.

The authors have declared no conflicts of interest. The authors report two cases of BP which began shortly after the initiation of PD-1 inhibitor therapy. One of the patients presented with metastatic ...

ABSTRACT: Bullous pemphigoid (BP) is the most prevalent autoimmune sub-epidermal blistering disease that affects mainly the elderly and could lead to serious morbidity. It has numerous risk factors ...